GlassScriptPhysician profile
Raj H Patel
NPI 1457710980
$1,807.74
in general payments reported to CMS, 2019-2025
19 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 81% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.31 · 2020: $24.98 · 2021: $43.17 · 2022: $167 · 2023: $150 · 2024: $204 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $477.46 | 2022-2025 | Breztri, Farxiga, Fasenra |
| Gilead Sciences, INC. | $281.94 | 2022-2025 | Biktarvy, Veklury |
| Novo Nordisk INC | $252.06 | 2019-2025 | Wegovy, Ozempic |
| Insmed, INC. | $138.59 | 2025 | Arikayce, Brinsupri |
| Boston Scientific Corporation | $135.00 | 2023 | Watchman Flx |
| Si-Bone, INC. | $130.93 | 2025 | |
| Viiv Healthcare Company | $74.11 | 2024-2025 | Cabenuva, Apretude |
| Biogen, INC. | $43.17 | 2021 | |
| Janssen Biotech, INC. | $33.71 | 2024-2025 | Stelara, Tremfya |
| Theratechnologies INC. | $33.70 | 2025 | Trogarzo, Egrifta |
| Amgen INC. | $33.20 | 2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $31.24 | 2024-2025 | Pifeltro, Delstrigo, Capvaxive |
| Glaxosmithkline, LLC. | $27.21 | 2019-2024 | Trelegy Ellipta |
| Tetraphase Pharmaceuticals, INC. | $24.98 | 2020 | |
| Xeris Pharmaceuticals, INC. | $23.00 | 2025 | Gvoke Hypopen |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $22.26 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Aimmune Therapeutics, INC. | $16.51 | 2025 | Vowst |
| Ani Pharmaceuticals, INC. | $15.06 | 2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $13.61 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.